IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study

Area of Science:

• Immunology
• Clinical Medicine
• Pharmacology

Background:

• Primary immunodeficiencies (PID) often involve recurrent infections.
• Standard immunoglobulin replacement therapy (IgRT) may be insufficient for some PID patients, particularly those with undetectable IgA and IgM.
• IgA and IgM are crucial for mucosal and complement-mediated immunity.

Purpose of the Study:

• To evaluate the safety and clinical outcomes of an IgA- and IgM-enriched immunoglobulin preparation (IgGAM) in PID patients with undetectable IgA/IgM and persistent infections.
• To assess the impact of IgGAM on infection rates, hospitalizations, and biological markers.

Main Methods:

• A compassionate use program (CUP) in France enrolled 20 PID patients.
• Patients received intravenous IgGAM infusions every 7-14 days.
• Safety, tolerance, infection frequency, hospitalizations, and immunological markers were prospectively analyzed.

Main Results:

• No severe adverse events were reported; mild hypersensitivity occurred in half the patients.
• Significant reductions in mean antibiotic courses (5.4 to 2.3/year) and hospitalizations (2.6 to 1.2/year) were observed.
• Serum IgA and IgM levels increased, with detectable IgA/IgM in saliva, indicating mucosal transfer.

Conclusions:

• IgGAM was associated with reduced infections and hospitalizations in severe PID patients with undetectable IgA/IgM.
• Further controlled studies are necessary to confirm the benefits of IgA/M-enriched immunoglobulin preparations.
• IgGAM shows promise for PID patients experiencing persistent or recurrent respiratory or digestive infections.